CSF1R and chronic myelogenous leukemia, BCR-ABL1 positive: One example being abl kinase inhibitors for chronic myeloid leukemia, such as Imatinib, having the ability of inhibiting c-fms, the M-CSF/CSF-1 receptor, with inhibitory effects on monocyte development, macrophage, and osteoclast activity (151, 152).